Izalontamab Brengitecan (BL-B01D1) (EGFR/HER3 Bispecific ADC)

2026-05-21 — Bristol Myers Squibb (NYSE: BMY) announced it will present oncology portfolio and pipeline data at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting (May 29–June 2, Chicago), citing more than 60 disclosures and 19 oral presentations across solid tumors and hematologic malignancies.

Key highlights include late-breaking full results from the Phase 3 SUCCESSOR-2 trial evaluating investigational oral CELMoD mezigdomide plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Additional presentations include safety and 12‑month efficacy for investigational lymphoma CELMoD golcadomide plus pola‑RCHP in newly diagnosed aggressive B‑cell lymphoma, and efficacy/safety of investigational CELMoD iberdomide with daratumumab/bortezomib/dexamethasone in newly diagnosed multiple myeloma.

In solid tumors, BMS notes Phase 3 results in China for izalontamab brengitecan (iza-bren; EGFRxHER3 bispecific ADC) in triple-negative breast cancer and esophageal squamous cell carcinoma (outside China, jointly developed with SystImmune), and Phase 2 data for pumitamig (PD‑L1 x VEGF‑A bispecific antibody) plus chemotherapy in first-line NSCLC (with BioNTech). The update signals broad late-stage and novel modality activity with potential competitive and partnering relevance.